Clinical Trial Update: A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease [Phase 2]

View source ↗

Summary

A Phase 2b trial evaluating AR-15512 ophthalmic solution for Dry Eye Disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• AR-15512 ophthalmic solution (AR-15512)

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Dry Eye Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-08-06